Once upon a time, there was an old man who used to go to the ocean to do his writing. He had a habit of walking on the beach every morning before he began his work. Early one morning, he was walking along the shore after a big storm had passed and found the vast […]
Author Archives: Dr James
30
Nov
Nov
The combination of Sovaldi (Sofosbuvir) and Daklinza (Daclatasvir) was the world’s first pan-genotypic Hepatitis C treatment. In the USA and Europe the $140,000 price tag of this combination means it has seen relatively little use, but in the world of generics it has seen extensive use because Daclatasvir is much cheaper to produce than either […]
20
Nov
Nov
Recently I have been getting a number of enquires from patients who have just finished their tablets, all asking the same questions, so here is a quick primer. If you are looking for this sort of information you will find a lot more detail in our Frequently Asked Questions and on the Forum. On treatment […]
16
Nov
Nov
Some time ago we saw some very bad science published. This suggested that treating Hepatitis C confers no benefits. While experts around the world expressed their firm view this was complete and utter rubbish here is something simple to understand. Get treated, get SVR and… you are far less likely to die of liver cancer. […]
Blogs
Pharmaniaga, Pharco and DNDi Sign Agreement to Provide Affordable Hepatitis C Treatment in Malaysia
13
Nov
Nov
KUALA LUMPUR/GENEVA – 13th November 2017 – Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd (Pharmaniaga), Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration agreement to supply a new hepatitis C treatment regimen to be sold for US$300 in the public sector […]
03
Nov
Nov
We have the power to FixHepC, but the real question is… Do we have the willpower? This was how Dr James Freeman ended his presentation at the World Hepatitis Summit in Brazil. You can watch the full presentation on YouTube. In essence, if we applied the same effort to HCV as we do to HIV […]
01
Nov
Nov
Hepatitis C is a disease that can make you feel old before your time. While there is no doubt that treatment with the new generation of direct acting antivirals like Harvoni is by far the best option this is not available to everyone, either because they don’t qualify under their insurance, don’t have insurance, or […]
19
Oct
Oct
About 1 in 100 people, from all walks of life, have Hepatitis C so it is pretty common. Because it is a highly stigmatised disease, linked in the public mind to IV drug use, most patients choose to keep their diagnosis confidential. Despite the fact that the evidence shows most patients were infected too young […]
05
Oct
Oct
Just out of embargo for AASLD 2017 is the rather innocuous sounding Abstract 1078 which says, in brief, that these generic DAAs are inarguably proven the same as the originator DAAs. Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals Andrew M. Hill1, Loai Tahat2, Mohammed Khalil Mohammed3, Sanjay Nath4, Rabab Fayez Tayyem3, James […]
Blogs
Bye bye limitatio (and generics) – Open access to the new Hepatitis C medications for all Swiss patients
21
Sep
Sep
Switzerland has just announced that all limitations on access to the new DAAs will be abolished allowing treatment for all. Great news for Swiss patients. Here is an article from the Swiss Hepatitis C Association about it. If you are not lucky enough to live in Switzerland generic versions of the new medications are available […]